Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of SCD411 versus Eylea in Neovascular Age-related Macular Degeneration
2019-004132-37Phase 3Completed
- Sponsor
- Sam Chun Dang Pharm Co., Ltd.
- Start
- May 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SCD411 in exudative macular degeneration (2 arms), sponsored by Sam Chun Dang Pharm Co., Ltd. Primary endpoint: Best corrected visual acuity (BCVA) at 8 weeks. Started May 2020; status: completed.
02
Drugs
SCD411
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2019-004132-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004132-37.